Among IDH+ LrGG patients, the full complement of metabolite data derived from 3-D MRSI helped to noninvasively differentiate tumor with respect to pathological grade, histological subtype (1p/19q codeletion), p53 expression, and NAWM. The gene discussed is IDH2; the disease is neoplasm.